Log in to search using one of your social media accounts:

 

The Future of TAVI The Future of TAVI
While TAVI has emerged as the established therapy for patients with severe, symptomatic aortic stenosis, there are still challenges that remain, and improvements that can be made.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Cardiac Amyloid Buildup Not Uncommon In TAVR Patients
(MedPage Today) -- Study opens question of interaction between aortic stenosis, amyloid (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 22, 2018 Category: Cardiology Source Type: news

Ashfield are shortlisted for a PM Award
Ashfield Digital & Creative, alongside our colleagues at Watermeadow Medical and our clients at Edwards Lifesciences, are thrilled to announce that we have been shortlisted for a PM Society Award in the Primary Care Campaign category for ‘Listen to the Heart’. A campaign focused on the lifesaving opportunity available to GPs through the early identification of aortic stenosis. Speaking about the collaboration, which led to this campaign, Ashfield Digital & Creative Senior Vice-President Andrew Binns said, “This entry demonstrates the impact that can be achieved when strategic insights and cre...
Source: Ashfield Healthcare News - January 18, 2018 Category: Pharmaceuticals Authors: Daniel Goodwin Tags: Ashfield Source Type: news

Edwards Lifesciences recalls Certitude delivery device for Sapien 3 valve
Edwards Lifesciences (NYSE:EW) is recalling the Certitude delivery device used with its Sapien 3 replacement heart valve on the risk that a molding defect could embolize, the FDA said today. The Sapien 3 is a transcatheter aortic valve replacement designed to treat aortic stenosis. During implantation the valve is crimped to Certitude’s balloon before either transapical or transaortic insertion into the body. The recall, of some lots made between Nov. 22, 2016, and July 10 of last year, is due to a molding overflow defect in the button valve within Certitude’s loader, according to the federal safety watchd...
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Recalls Replacement Heart Valves Edwards Lifesciences Source Type: news

3 Reasons TAVR Will Continue to Prosper
The transcatheter aortic valve replacement (TAVR) market has already seen rapid growth, and today represents a $3 billion market globally. But the leading TAVR companies say the current technology and approved indications barely scratches the surface in terms of the true growth potential of the space. Michael Mussallem, CEO of Edwards Lifesciences, told J.P. Morgan Healthcare Conference attendees on Monday that the global TAVR market is expected to exceed $5 billion by 2021, and that number does not include certain indications that are currently being explored, like treatment for patients with asymptomatic aortic...
Source: MDDI - January 9, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news

Impaired Survival With LVEF < 60 Percent in Aortic Stenosis
Poorer outcomes seen for LVEF (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 5, 2018 Category: Respiratory Medicine Tags: Cardiology, Nursing, Pathology, Pulmonology, Critical Care, Journal, Source Type: news

' Normal' LVEF: Misnomer in Aortic Stenosis?
(MedPage Today) -- Study shows survival in severe aortic stenosis impaired with LVEF (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 27, 2017 Category: Cardiology Source Type: news

Can Boston Scientific Bounce Back from Lotus Setback?
Boston Scientific shares took a beating Tuesday after the company abruptly backed out of a scheduled appearance at the annual Piper Jaffray healthcare conference in New York. As investors seemed to fear, the sudden change of plans foreshadowed another Lotus setback. The company's stock (NYSE: BSX) dropped 7.5% by market close on Tuesday, slashing Boston Scientific's market cap by about $2.9 billion. About three hours after the close, the company said it had pushed back its previously-reported timelines for re-introducing the Lotus Edge aortic valve system in Europe, and the filing of a final pre-market approval (PMA) modul...
Source: MDDI - November 29, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Cardiovascular Source Type: news

Boston Scientific takes a $3B hit on latest Lotus valve delay
Boston Scientific (NYSE:BSX) saw its market capitalization lose $3 billion after yesterday revealing another delay for its Lotus replacement heart valve. The Marlborough, Mass.-based company, which recalled the Lotus transcatheter aortic heart valve in February over issues with its locking mechanism, said it no longer expects the ensuing manufacturing and design specification changes to get the valve back on the market in Europe or allow the final filing in its pre-market approval bid with the FDA by January 2018. “We continue to see value in the unique benefits of the LOTUS Valve platform in treating patients w...
Source: Mass Device - November 29, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Replacement Heart Valves Wall Street Beat Boston Scientific Source Type: news

Afternoon open heart surgery 'leads to fewer complications'
Conclusion This study found evidence of an effect that's worth investigating further to see if there are real differences in heart muscle function and risk of complications from heart surgery at different times of the day. However, there were some limitations: It took place at a single hospital, with a relatively small number of people undergoing operations. The laboratory study found differences in gene activity that suggested the body clock may play a role in making the heart better able to tolerate loss of oxygen and subsequent re-oxygenation. However, there may be other explanations for these differences. For example, ...
Source: NHS News Feed - October 27, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

RAS Blockade After TAVI Tied to Better Outcomes (CME/CE)
(MedPage Today) -- Patients with severe aortic stenosis see reduced all-cause mortality (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - October 26, 2017 Category: Urology & Nephrology Source Type: news

All-Time High for Obesity; Aortic Stenosis AUC; Prognosticating Cardiac Arrest
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - October 20, 2017 Category: Pediatrics Source Type: news

TAVR Looms Large in First AUC Document for Severe Aortic Stenosis TAVR Looms Large in First AUC Document for Severe Aortic Stenosis
There are more treatment options than ever before, but guidelines only go so far when the patient is 90-something, frail, and with multiple chronic disorders, for example.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Appropriate Use Criteria Developed for Aortic Stenosis Tx
SAVR or TAVR appropriate for most patients with symptomatic AS at intermediate or high surgical risk (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 18, 2017 Category: Respiratory Medicine Tags: Cardiology, Nursing, Pulmonology, Surgery, Journal, Source Type: news

First Appropriate Use Criteria for Severe Aortic Stenosis Published (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American College of Cardiology, the American Heart Association, and nine other medical groups have issued the first-ever appropriate use criteria for treating severe aortic stenosis.The … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 18, 2017 Category: Primary Care Source Type: news

First Appropriate Use Criteria Issued for Severe Aortic Stenosis
(MedPage Today) -- Multi-society guide OKs intervention for most symptomatic cases (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 17, 2017 Category: Primary Care Source Type: news

Shockwave Medical raises $35m for Lithoplasty devices
Shockwave Medical said today that it raised another $35 million for the Lithoplasty devices it’s commercializing to treat blocked arteries. Fremont, Calif.-based Shockwave said it plans to use the new funding, which was led by new backer Fidelity Management & Research, to commercialize its existing devices for treating coronary and peripheral vessels in the U.S. and Europe and to evaluate the Lithoplasty tech in treating aortic valve stenosis. T. Rowe Price Assoc. also participated in the financing, which Shockwave said was an extension of its $45 million Series C round. The Lithoplasty devices are...
Source: Mass Device - October 10, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Ultrasound Wall Street Beat peripheral Shockwave Medical Source Type: news

Medtronic launches post-market study of CoreValve Evolut Pro heart valve
Medtronic (NYSE:MDT) said today it launched a post-market clinical study of its CoreValve Evolut Pro valve, looking to evaluate performance out to 5 years for the self-expanding transcather aortic valve implantation system. The multi-center, prospective single-arm study aims to enroll 600 patients across 35 European sites to evaluate the safety of the CoreValve Evolut Pro, including all-cause mortality and all stroke at 30 days and clinical performance including valve hemodynamics and paravalvular regurgitation. “We look forward to replicating the excellent clinical outcomes demonstrated by the Evolut Pro valve ...
Source: Mass Device - September 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Medtronic Source Type: news

Medical societies expand collaboration on cardiac registry
The American Society of Nuclear Cardiology (ASNC) and the American Society...Read more on AuntMinnie.comRelated Reading: ASNC, SNMMI advise on cardiac sarcoidosis ASNC releases guidance on MPI in women ASE: Echo protocol finds kids' heart abnormalities Echo groups release guidance on aortic stenosis Echo groups release new stress echo guidelines (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 19, 2017 Category: Radiology Source Type: news

Regular Evaluation Improves Survival in Asymptomatic Severe AS Regular Evaluation Improves Survival in Asymptomatic Severe AS
Patients with asymptomatic severe aortic stenosis followed according to guideline recommendations were more likely to undergo early valve replacement and had improved survival and reduced hospitalization.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 18, 2017 Category: Radiology Tags: Cardiology News Source Type: news

New educational resource to help GPs detect aortic stenosis early
A new interactive educational resource for GPs has been launched to support the early detection of aortic stenosis. (Source: GP Online News)
Source: GP Online News - September 14, 2017 Category: Primary Care Tags: 15.1 Cardiovascular Problems Source Type: news

Do You Listen to Heart Sounds? This May be Another Reason Why You Should.
I’m not sure about you, but when I went to school to become a paramedic (and a nurse for that matter), one thing I never really understood was heart sounds, or heart tones, depending on who taught you. My attempt at learning resorted to scouring textbooks, journals, online editorials, watching clips on YouTube and listening… lots of listening to sound bites from CDs. You know the ones, they come free when you buy a new stethoscope. Instead of turning to digital media, I should’ve been listening to the hearts of my patients. Hindsight is 20/20, especially in this case. All my self-guided education yielded...
Source: JEMS Patient Care - September 12, 2017 Category: Emergency Medicine Authors: Bruce Hoffman, MSN,BSN-RN, NR-P, CFRN Tags: Patient Care Cardiac & Resuscitation Source Type: news

Tall VTE Risk; Frequent Aortic Stenosis Checks;'Sweet Spot' for LVAD Volume
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 8, 2017 Category: Cardiology Source Type: news

Close Watch on Aortic Stenosis May Improve Outcomes
(MedPage Today) -- Single-center study supports guideline-based serial evaluations for asymptomatic patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 7, 2017 Category: Cardiology Source Type: news

Serial Echos Valuable in Patients with Asymptomatic Severe Aortic Stenosis (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM Patients with asymptomatic severe aortic stenosis who don't get regular evaluations are at increased risk for death and heart failure, according to a retrospective study in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 7, 2017 Category: Primary Care Source Type: news

Not adhering to recommended exams for severe narrowing of the aortic valve associated with increased heart failure
(The JAMA Network Journals) Patients with asymptomatic severe aortic stenosis who did not follow recommended guidelines for regular exams had poorer survival and were more likely to be hospitalized for heart failure, according to a study published by JAMA Cardiology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 6, 2017 Category: International Medicine & Public Health Source Type: news

Intervention for Aortic Stenosis: Frailty Matters Intervention for Aortic Stenosis: Frailty Matters
The FRAILTY-AVR study evaluated different frailty scales in predicting poor outcomes following TAVR and SAVR. What did we learn and how will it influence clinical practice?Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Nonagenarians'Good Candidates' for TAVI Surgery Nonagenarians'Good Candidates' for TAVI Surgery
Severe aortic-stenosis patients aged 90 years or older can be candidates for transcatheter aortic-valve implantation, with similar outcomes to those in younger patients, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Cardiopulmonary Exercise Testing Prognostic in Aortic Stenosis
Conservative strategy results in good prognosis if CPET does not indicate hemodynamic compromise (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 25, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Pulmonology, Geriatrics, Journal, Source Type: news

Next-gen Repositionable Self-expanding Catheter Safe for Severe Aortic Stenosis Next-gen Repositionable Self-expanding Catheter Safe for Severe Aortic Stenosis
The self-expanding, repositionable Evolut R transcatheter heart valve (THV) from Medtronic appears safe and effective for treating older patients with severe aortic stenosis, according to a company-funded observational study.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2017 Category: Consumer Health News Tags: News Source Type: news

Medtronic wins FDA nod, CE Mark for Avalus aortic valve
Medtronic (NYSE:MDT) said today it won CE Mark approval in the European Union and FDA approval in the US for its Avalus pericardial aortic surgical valve designed to treat aortic valve disease. The Avalus is the Fridley, Minn.-based company’s next-gen pericardial surgical aortic valve, and features a supra-annular design to improve hemodynamic performance and limit central regurgitation. The valve also features interior-mounted leaflet and frame design for improved durability and a low-profile design with a streamlined valve holder and single, one-cut release for easier implantations, Medtronic said. “Medt...
Source: Mass Device - August 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves Medtronic Source Type: news

Medtronic touts reduced costs, rehospitalizations in cryoballoon vs RF AF ablation trial analysis
Medtronic (NYSE:MDT) today released data from a health economic analysis from the Fire And Ice trial comparing its Arctic Front cryoballoon catheter to its ThermoCool radiofrequency ablation cath, touting that cryoballoon treatment could reduce costs and rehospitalizations when used to treat paroxysmal atrial fibrillation. Economic analysis results from the trial were published today in the Journal of the American Heart Association. Researchers analyzed data from the 769-patient trial, which Medtronic claims is the largest to compare cryoballoon ablation to point-by-point RF ablation for treating paroxysmal AF, o...
Source: Mass Device - August 1, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Medtronic Source Type: news

Medtronic wins CE Mark for CoreValve Evolut Pro
Medtronic (NYSE:MDT) said today it won CE Mark approval in the European Union for its CoreValve Evolut Pro transcatheter aortic heart valve, indicated for the treatment of severe aortic stenosis for symptomatic patients at intermediate, high or extreme risk for open heart surgery The CoreValve Evolut Pro features an outer wrap to add surface area contact between the valve and the native aortic annulus to increase valve sealing performance, Fridley, Minn.-based Medtronic said. “We are excited to introduce the next evolution of our Evolut TAVI platform to provide physicians in Europe with a comprehensive portfolio...
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Regulatory/Compliance Replacement Heart Valves Medtronic Source Type: news

Experience Journal: A bereaved mother ’s lessons from the heart
Jessica Lindberg’s son Ethan was a brave heart warrior whose journey at Boston Children’s Hospital began before he was even born. At 20 weeks, they learned he had aortic stenosis and evolving hypoplastic left heart syndrome (HLHS). At 22 weeks Ethan was the 30th baby to have an in-utero procedure to open his aortic valve and relieve pressure in the left side of his heart. By the time Ethan was 2, he’d had four open-heart surgeries. He was also having feeding problems, developmental delays, and was struggling with executive functioning and spatial tasks. Like many other parents of children with congen...
Source: Thrive, Children's Hospital Boston - July 27, 2017 Category: Pediatrics Authors: Ellen Greenlaw Tags: Diseases & Conditions Our Patients’ Stories Cardiac Neurodevelopmental Program congenital heart defect Dr. Janice Ware Experience Journal Heart Center hypoplastic left heart syndrome Source Type: news

3D printing helps evaluate leaks after TAVR procedures
3D-printed phantoms of aortic root anatomy offer a noninvasive way to assess...Read more on AuntMinnie.comRelated Reading: Echo groups release guidance on aortic stenosis ACC: CT detects blood clots that reduce valve motion CT better than echo for aortic annulus before TAVR Study finds differences in CCTA plaque measurements Cutting-edge techniques transform practice of cardiac CT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 26, 2017 Category: Radiology Source Type: news

Stress Echo Value Questioned for Asymptomatic Aortic Stenosis
Neither increase in mean pressure gradient, systolic pulmonary artery pressure predicted outcome (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 26, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Nursing, Pulmonology, Radiology, Journal, Source Type: news

Morristown Medical Center Randomizes First Patient in World to New...
Morristown Medical Center Randomizes First Patient in World to New Study to Evaluate Treatment for Asymptomatic Severe Aortic Stenosis; Trial may change treatment paradigm, save heart muscle(PRWeb July 13, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14507855.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 13, 2017 Category: Pharmaceuticals Source Type: news

Study: TAVR, surgical AVR results similar at 2 years in intermediate risk patients
Transcatheter and surgical aortic valve procedures were shown to have similar outcomes at 2 years in severe aortic stenosis patients deemed to be at intermediate surgical risk, according to a recently published study. Data came from a 2-year follow up with patients in the Partner 2 trial, which aimed to explore the difference between the 2 procedures in intermediate risk patients. A total of 2,032 patients were examined in the trial, which was randomly divided into 2 cohorts, with the 1st receiving Edwards Lifesciences‘(NYSE:EW) Sapien XT and the 2nd receiving a surgical AVR procedure. At 2 years, both disease-s...
Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Replacement Heart Valves Edwards Lifesciences Source Type: news

FDA Expands CoreValve TAVR Indication to Intermediate-Risk Patients FDA Expands CoreValve TAVR Indication to Intermediate-Risk Patients
The expanded indication to include treatment of patients with severe aortic stenosis at intermediate risk for surgery is based on the pivotal SURTAVI data reported this March.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

FDA Gives Approval to Medtronic's CoreValve for Use in Patients at Intermediate Risk for Surgical Valve Replacement
Based on results from the landmark SURTAVI Clinical Trial, presented at the American College of Cardiology Annual Meeting in March, and published in the New England Journal of Medicine, the FDA has approved the CoreValve TAVR self-expanding platform for use in patients with severe and symptomatic aortic stenosis who are at "intermediate" risk for surgical valve replacement, defined as mortality>= 3% at 30 days. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 10, 2017 Category: Cardiology Source Type: news

FDA clears Medtronic ’ s CoreValve Evolut TAVR in intermediate risk patients
Medtronic (NYSE:MDT) said today it won expanded FDA approval for its CoreValve Evolut transcather aortic valve replacement platform, now indicated for patients with symptomatic severe aortic stenosis who are at an intermediate risk for open heart surgery. The Fridley, Minn.-based company said that patients at intermediate risk for open-heart surgery have a mortality risk of greater than or equal to 3% at 30 days following the procedure. “Patients at intermediate risk for open-heart surgery account for a large portion of the severe aortic stenosis population. We are delighted to take the self-expanding CoreV...
Source: Mass Device - July 10, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves Medtronic Source Type: news

7 medtech stories we missed this week: June 9, 2017
[Image from unsplash.com]From 3M’s expanded 510(k) clearance for its Tegaderm dressing to Medtronic and Acacia burying the hatchet, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. InspireMD inks Taiwanese distro deal for CGuard InspireMD announced in a June 8 press release that it has signed a distribution deal with Lorion Enterprises. The deal will expand InspireMD’s global footprint and distribute its CGuard Embolic Prevention System (EPS) through the medical device distributor in Taiwan. 2. Active Implants launches NUsurface knee trial Active Implants announced...
Source: Mass Device - June 9, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Business/Financial News Clinical Trials Food & Drug Administration (FDA) Implants Regulatory/Compliance 3m Acacia Research Corp. Active Implants Advanced Cooling Therapy Attune Medical Exactech Inc. HLT InspireMD MedTech Source Type: news

ASE: Echo protocol finds kids' heart abnormalities
A new echocardiography protocol can detect early functional abnormalities in...Read more on AuntMinnie.comRelated Reading: Digisonics readies upgrades for ASE 2017 Echo groups release guidance on aortic stenosis Echo groups release new stress echo guidelines ASE debuts new educational offerings ASE offers guide for childhood heart disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 2, 2017 Category: Radiology Source Type: news

TAVR in the Care of Older Persons With Aortic Stenosis TAVR in the Care of Older Persons With Aortic Stenosis
This article reviews current literature on the safety and feasibility of transcatheter aortic valve replacement in the elderly, focusing on frailty as an aid to prognosis and decision-making.Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Robot hearts: medicine ’s new frontier
From bovine valves to electrical motors and 3-D printed hearts, cardiologists are forging ahead with technologies once dismissed as “crazy ideas”On a cold, bright January morning I walked south across Westminster Bridge to St Thomas ’ Hospital, an institution with a proud tradition of innovation: I was there to observe a procedure generally regarded as the greatest advance in cardiac surgery since the turn of the millennium – and one that can be performed without a surgeon.The patient was a man in his 80s with aortic stenosis, a narrowed valve which was restricting outflow from the left ventricle in...
Source: Guardian Unlimited Science - May 23, 2017 Category: Science Authors: Thomas Morris Tags: Science Health Society Heart attack Technology Engineering Source Type: news

High Risk of Clinical Events With Moderate Aortic Stenosis Plus LVSD High Risk of Clinical Events With Moderate Aortic Stenosis Plus LVSD
The combination of moderate aortic stenosis and left ventricular systolic dysfunction (LVSD) is associated with a high risk of heart failure hospitalization and death, researchers report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 12, 2017 Category: Radiology Tags: News Source Type: news

Princeton Baptist Medical Center offers new aortic procedure
Princeton Baptist Medical Center has performed the first surgery in the state using a new treatment for severe aortic stenosis. It's the first facility in the Southeast to offer the technology - a new transcatheter aortic valve replacement procedure with a self-expanding implant and advanced sealing. The newly FDA-approved CoreValve Evolut PRO TAVR is for symptomatic patients who are at high or extreme risk for open heart surgery. “One of our strongest areas of expertise is treating patients… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 18, 2017 Category: American Health Authors: Stephanie Rebman Source Type: news

Conscious sedation is a safe alternative to general anesthesia for heart valve procedure
FINDINGSUCLA scientists have found that conscious sedation — a type of anesthesia in which patients remain awake but are sleepy and pain-free — is a safe and viable option to general anesthesia for people undergoing a minimally invasive heart procedure called transcatheter aortic valve replacement.In the study, patients who underwent conscious sedation had a similar rate of adverse events to those who underwent anesthesia, but those who were given conscious sedation had shorter stays in the intensive care unit (30 versus 96 hours for those with general anesthesia) and shorter hospital stays (4.9 days versus 10....
Source: UCLA Newsroom: Health Sciences - April 11, 2017 Category: Universities & Medical Training Source Type: news

Echo groups release guidance on aortic stenosis
The European Association of Cardiovascular Imaging and the American Society...Read more on AuntMinnie.comRelated Reading: Echo groups release new stress echo guidelines ASE debuts new educational offerings ASE offers guide for childhood heart disease ASE elects new president ASE: Aortic flow rate predicts risk of heart failure (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 3, 2017 Category: Radiology Source Type: news

Medtronic Receives FDA Approval for CoreValve ™ Evolut™ Pro Transcatheter Valve with Advanced Sealing
Medtronic plc (NYSE:MDT) today announced FDA approval and U.S. launch of the CoreValve ™ Evolut™ PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at high or extreme risk for open heart surgery. The approval comes on the heels of new 30-day clinical data that was unveiled at the American College of Cardiology (ACC) 66th Annual Scientific Sessio n, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics for the self-expanding valve. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 22, 2017 Category: Cardiology Source Type: news